Calista`s investors completed a co-investment in EMERGEX VACCINES, alongside leading tech investor fund, Vickers Venture Partners, a long-standing friend and partner of Calista.
Emergex, a Cambridge, UK-based company, combines validated technologies together with the very latest scientific insights to develop its vaccines that could provide long-term immunity to many pathogens, including such as viruses that cause diseases such as COVID-19, Dengue, Zika, Ebola, pandemic flu, as well as serious intracellular bacterial infections.
Led by its founder, Professor Thomas Rademacher, the company`s synthetic vaccine programs T-cells to recognise, kill virus-infected cells and develop broad and durable memory T-cell immunity akin to that produced by natural infection, without the risks of falling ill.
Emergex's platform nanoparticle technology induces robust memory T-cell immunity instead of antibodies. The technology enables rapid design of vaccines candidates to deal with rapidly evolving viruses, and their vaccines are simpler and more cost-effective to produce than existing vaccine technologies.
Emergex vaccines have been designed to be administered via the skin using microneedles and to be stable at ambient room temperature for beyond three months, facilitating rapid and efficient distribution across the world even in places with limited cold chain capabilities, enabling more patient friendly administration of the vaccine.
Emergex commenced their Swiss Phase I clinical trial to test their dengue vaccine candidate in August 2021. The COVID-19 vaccine candidate trial arm began in January 2022. In December 2021, Emergex confirmed that its vaccine candidate for SARS-CoV-2, the virus which causes COVID-19, has the potential to be effective against all currently known variants.